Basic principles of physiologically-based pharmacokinetic (PBPK) modeling and its impact in streamlining the drug development process are reviewed.
Jens Sydor
Advertisement
Jens Sydor is vice-president, DMPK, GlaxoSmithKline.
Articles by Jens Sydor
Advertisement
Latest Updated Articles
Enabling the Virtual Human Through Physiologically-based Pharmacokinetic ModelingPublished: March 16th 2021 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
BioPharm Weekly News Roundup—Week of Oct. 20, 2025
2
Orion and Abzena Collaboration Highlights Integrated Antibody Manufacturing Advances
3
From Parm to Pharm: Avantor, p-Chip Bring COI Compliance to Clinical Consumables
4
SK pharmteco Invests in California Site to Overcome Peptide Purification Bottlenecks
5
